Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Ischemic stroke, a leading cause of death and disability worldwide, arises predominantly from atherosclerosis and thromboembolic occlusion of cerebral arteries. While advancements in acute interventions such as thrombolysis and thrombectomy have improved outcomes, the identification of upstream molecular drivers remains essential for better prevention and risk stratification. Among these, circulating apolipoproteins, the structural and regulatory proteins of lipoprotein particles, are increasingly recognized as pivotal mediators at the intersection of lipid metabolism, inflammation, endothelial dysfunction and thrombosis. This review summarizes recent evidence on the diverse roles of apolipoproteins in systemic vascular biology and their contributions to stroke initiation. We examine how specific apolipoproteins influence atherogenesis, plaque instability, coagulation factor dynamics, immune-endothelial interactions and platelet adhesion. Emerging data suggest that functional imbalances among apolipoproteins, independent of conventional lipid levels, may serve as superior predictors of stroke risk and reveal novel mechanistic links between dyslipidemia, immune cell activation and thrombo-inflammation. By bridging insights from lipidology, vascular biology and thrombosis research, we position apolipoproteins as promising biomarkers and therapeutic targets to reduce the burden of ischemic stroke and improve cerebrovascular health.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.plipres.2025.101343 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improved Cardiac Structure and Ventricular-Arterial Coupling After Baroreflex Activation Therapy.
JACC Case Rep
September 2025
Cardiovascular Division, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Electronic address:
Baroreflex activation therapy (BAT) improves functional status, quality of life, and exercise capacity in patients with heart failure with reduced ejection fraction; however, its direct effects on reversing adverse cardiac remodeling as assessed by improvements in cardiac structure, function, and coupling with the arterial system remain unclear. We present 2 cases of patients who initially presented with decompensated heart failure, and despite initial medical therapy and continued outpatient follow-up, were unable to tolerate full escalation of guideline-directed medical therapy. The patients remained symptomatic, with high biomarker levels, poor functional capacity, severe heart failure symptoms, and objectively had decreased stroke volume, low left ventricular ejection fraction, and high left ventricular mass.
View Article and Find Full Text PDFFrom Evidence to Bedside: The Role of Short-Acting β-Blockers in Sepsis Care.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Sepsis remains a leading cause of critical illness and mortality worldwide, driven by a dysregulated host response to infection and often complicated by persistent tachycardia and cardiovascular dysfunction. Increasing evidence implicates excessive sympathetic activation as a contributor to sepsis-related hemodynamic instability and myocardial injury, prompting growing interest in the use of β-adrenergic blockade as a therapeutic adjunct. This review synthesizes current data on the safety and efficacy of short-acting, cardioselective β-blockers (BBs), particularly esmolol and landiolol, in septic shock.
View Article and Find Full Text PDFSerum Lipidomics Profiling to Identify Potential Biomarkers of Ischemic Stroke: A Pilot Study in Chinese Adults.
Biomed Environ Sci
August 2025
Department of Epidemiology, School of Public Health, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou 215123, Jiangsu, China;Taixing Second People's Hospital, Suzhou Medical College of Soochow University, Taizhou 225400, Jiangsu, China.
Objective: Lipid oxidation is involved in the pathogenesis of atherosclerosis and may be contribute to the development of Ischemic stroke (IS). However, the lipid profiles associated with IS have been poorly studied. We conducted a pilot study to identify potential IS-related lipid molecules and pathways using lipidomic profiling.
View Article and Find Full Text PDFImpact of Urate-Lowering Therapy after Percutaneous Coronary Intervention on the Long- Term Prognosis of Patients with Hyperuricemia.
Kardiologiia
September 2025
Department of Cardiology, The Ninth Medical Center, Chinese PLA General Hospital.
Background Hyperuricemia (HUA) frequently coexists with coronary artery disease (CAD) and is linked to adverse cardiovascular outcomes. The long-term impact of urate-lowering therapy (ULT) on clinical outcomes, including all-cause mortality and major adverse cardiovascular events (MACEs), in CAD patients after percutaneous coronary intervention (PCI) has not been determined. That was the aim of this study.
View Article and Find Full Text PDFEfficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial.
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.